Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
The European Journal of Health Economics
Published in: The European Journal of Health Economics 3/2009

01-07-2009 | Original Paper

The economic costs of Group B Streptococcus (GBS) disease: prospective cohort study of infants with GBS disease in England

Authors: Elizabeth-Ann Schroeder, Stavros Petrou, Gail Balfour, Oya Edamma, Paul T. Heath, on behalf of the Health Protection Agency Group B Streptococcus Working Group

Published in: The European Journal of Health Economics | Issue 3/2009

Login to get access

Abstract

The objective of this study was to estimate the economic costs over the first 2 years of life of Group B Streptococcus (GBS) disease occurring in infants less than 90 days of age. A cost analysis was conducted using a prospective cohort of children born between 2000 and 2003 in the Greater London, Oxford, Portsmouth and Bristol areas of England. Unit costs were applied to estimates of the health and social resource use made by 138 infants diagnosed with GBS disease and 305 non-GBS controls matched for birth weight and hospital stay and time of birth. The health and social care costs for infants exposed to GBS disease were analysed in a multiple linear regression model. The mean health and social care cost over the first 2 years of life was estimated at £11,968.9 for infants with GBS, compared to £6,260.7 for the non-GBS controls; a mean cost difference of £5,708.1 (bootstrap 95% CI £2,977.1, £8,391.2, P = 0.03). After adjusting for gestational age and other potential confounders in a multiple linear regression, mean societal costs was £6,144.7 higher among GBS cases than among non-GBS controls (P < 0.001). This study shows that the health and social care costs for infants with GBS disease is, on average, two-fold higher during the first 2 years of life than for infants without GBS disease. These data should be used to inform policy decisions regarding the cost-effectiveness of prevention and treatment strategies for GBS disease during early childhood.
Literature
1.
van den Akker-van Marle, M.E., Rijnders, M.E.B., Fekkes, M., Amelink-Verburg, M.P., van Dommelen, P., Verkerk, P.H.: Cost-effectiveness of different treatment strategies with intrapartum antibiotic prophylaxis to prevent early onset group B streptococcal disease. Health Econ. 1, 85–92 (1992). doi:10.​1002/​hec.​4730010202
2.
Colbourn, T., Asseburg, C., Bojke, L., Philips, Z., Welton, N., Claxton, K., et al.: Preventive strategies for group B streptococcal and other bacterial infections in early infancy: cost effectiveness and value of information analyses. BMJ 335, 655 (2007). doi:10.​1136/​bmj.​39325.​681806.​AD CrossRef
3.
4.
Law, M.R., Palmomaki, G., Alfirevic, Z., Gilbert, R., Heath, P., McCartney, C., et al.: The prevention of neonatal group B streptococcal disease. J. Med. Screen. 12(2), 60–68 (2005). doi:10.​1258/​0969141053908366​ CrossRef
5.
6.
7.
8.
9.
Heath, P., Balfour, G., Weisner, A.M., Efstratiou, A., Lamagni, T.L., Tighe, H., et al.: Group B streptococcal disease in UK and Irish infants younger than 90 days. Lancet 363, 292–293 (2004). doi:10.​1016/​S0140-6736(03)15389-5 CrossRef
10.
Easmon, C.S., Hastings, M.J., Clare, A.J., Bloxham, B., Marwood, R., Rivers, R.P., et al.: Nosocomial transmission of group B streptococci. Br. Med. J. (Clin. Res. Ed.). 283(6289), 459–461 (1981)
11.
12.
Early-Onset and Late-Onset Neonatal Group B Streptococcal Disease—United States, 1996–2004: Morb. Mortal. Wkly Rep. 2. 54(47), 1205–1208 (2005)
13.
Nicoll, A., Heath, P.T.: Group B streptococcal infection. Arch. Dis. Child. Fetal. Neonatal. Ed. 82, F207 (2000)
14.
National Institute for Health and Clinical Excellence (NICE): Guide to the Methods of Technology Appraisal. NICE, London (2004)
15.
16.
Drummond, M.F., Jefferson, T.O.: Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ economic evaluation working party. BMJ 313, 275–283 (1996)
17.
Drummond, M.F., O’Brien, B., Stoddart, G.L., Torrance, G.W.: Methods for the economic evaluation of health care programmes, 3rd edn. Oxford University Press, Oxford (2005)
18.
Netten, A., Curtis, L.: Unit costs of health and social care. Canterbury: Personal Social Services Research Unit, University of Kent (2003)
19.
Allen, C., Beecham, J.: Costing services: ideals and reality. In: Netten, A., Beecham, J. (eds.) Costing Community Care: Theory and Practice, pp. 25–42. Ashgate, Aldershot (1995)
20.
British Medical Association and Royal Pharmaceutical Society of Great Britain: British National Formulary (September). BMJ Books and Pharmaceutical Press, London (2000)
21.
Treasury, H.M.: Value for Money Assessment Guidance. HM Treasury, London (2004)
22.
Briggs, A., Clark, T., Wolstenholme, J., Clarke, P.: Missing… presumed at random: cost-analysis of incomplete data. Health Econ. 12(5), 377–392 (2003). doi:10.​1002/​hec.​766 CrossRef
23.
Thompson, S.G., Barber, J.A.: How should cost data in pragmatic randomized trials be analyzed? BMJ 320, 1197–1200 (2000)CrossRef
24.
Dixon, P.M.: The bootstrap and the jackknife: describing the precision of ecological indices. In: Design and Analysis of Ecological Experiments, pp. 290–318. Chapman and Hall, New York (1993)
25.
Briggs, A.H., Wonderling, D.E., et al.: Pulling cost-effectiveness up by its bootstraps: a non-parametric approach to confidence interval estimation. Health Econ. 6(4), 327–340 (1997). doi :10.1002/(SICI)1099-1050(199707)6:4<327::AID-HEC282>3.0.CO;2-WCrossRef
26.
Tucker, J., Tarnow-Mordi, W., Gould, C., et al.: UK neonatal intensive care services in 1996. On behalf of the UK Neonatal Staffing Study Collaborative Group. Arch. Dis. Child Fetal. Neonatal. Ed. 80, F233–F234 (1999)CrossRef
27.
28.
Phares, C.R., Lynfield, R., Farley, M.M., Mohle-Boetani, J., et al.: Epidemiology of invasive Group B Streptococcal disease in the United States, 1999–2005. JAMA 299(17), 2056–2065 (2008)CrossRef
29.
30.
31.
Petrou, S., Kupek, E., Hockley, C., Goldacre, M.: Social class inequalities in childhood mortality and morbidity in an English population. Paediatr. Perinat. Epidemiol. 20, 14–23 (2006)CrossRef
Metadata
Title
The economic costs of Group B Streptococcus (GBS) disease: prospective cohort study of infants with GBS disease in England
Authors
Elizabeth-Ann Schroeder
Stavros Petrou
Gail Balfour
Oya Edamma
Paul T. Heath
on behalf of the Health Protection Agency Group B Streptococcus Working Group
Publication date
01-07-2009
Publisher
Springer-Verlag
Published in
The European Journal of Health Economics / Issue 3/2009
Print ISSN: 1618-7598
Electronic ISSN: 1618-7601
DOI
https://doi.org/10.1007/s10198-008-0131-4

Other articles of this Issue 3/2009

The European Journal of Health Economics 3/2009 Go to the issue

Original Paper

The cost of resistance: incremental cost of methicillin-resistant Staphylococcus aureus (MRSA) in German hospitals

Original Paper

Hybrid risk adjustment for pharmaceutical benefits

Original Paper

Exploring spatial patterns in general practice expenditure

Original Paper

Modelling health expenditure at the household level in Greece

Original Paper

Total costs of injury from accidents in the home and during education, sports and leisure activities: estimates for Norway with assessment of uncertainty

Editorial

Why the econometrician is in good spirits: a workshop through the looking glass